How are you requesting testing for HER2-ultralow status, in light of DB-06 trial demonstrating benefit of T-DXd for these patients?

Community PollStarted

How, if at all, are you incorporating HER2-ultralow status testing into your practice?

50 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers

Mednet Member

Medical Oncology · UC San Diego School of Medicine

Answered on

I have asked our breast pathologists to routinely report it on all new samples and if I have a metastatic patient that might be a candidate, I have had pathology go back and stain all their prior samples for it. I’ve now used T’ Dxd in many ultralow patients and it works beautifully.

Join for free or sign in to see the full answer

Mednet MemberInvited Expert

Medical Oncology · The University of Texas MD Anderson Cancer Center

Answered on

The DESTINY-Breast06 clinical trial enrolled patients with hormone receptor positive (HR+), HER2-low, and HER2-ultralow metastatic breast cancer. Ultralow is defined as IHC greater than 0 but <1. The current ASCO CAP guidelines incorporate both HER2 null (no staining) and HER2 ultralow as IHC 0. At ...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert

Medical Oncology · Harvard Medical School

Answered on

Our pathologists now automatically read out HER2 IHC 0 as either "IHC 0; ultralow" or "IHC 0; null." However, this is not yet in the ASCO/CAP guidelines and this may not be the case at many institutions.

Join for free or sign in to see the full answer